My NCBISign In
Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis?
Jan O Friedrich, Neill KJ Adhikari, Maureen O Meade
Crit Care. 2006; 10(3): 145. Published online 2006 June 2. doi: 10.1186/cc4947
PMCID:
PMC1550958
Abstract Full Text PDF–210K

Is Cited by the Following 11 Articles in this Archive:

ANTAGONISM OF α2A-ADRENOCEPTOR: A NOVEL APPROACH TO INHIBIT INFLAMMATORY RESPONSES IN SEPSIS
Fangming Zhang, Rongqian Wu, Xiaoling Qiang, Mian Zhou, Ping Wang
J Mol Med (Berl) Author manuscript; available in PMC 2011 March 1.
Published in final edited form as: J Mol Med (Berl). 2010 March; 88(3): 289–296. Published online 2009 November 6. doi: 10.1007/s00109-009-0555-z
PMCID:
PMC2837104
Abstract Full Text PDF–678K
Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock
Simon Finfer, V. Marco Ranieri, B. Taylor Thompson, Philip S. Barie, Jean-François Dhainaut, Ivor S. Douglas, Bengt Gårdlund, John C. Marshall, Andrew Rhodes
Intensive Care Med. 2008 November; 34(11): 1935–1947. Published online 2008 October 7. doi: 10.1007/s00134-008-1266-6
PMCID:
PMC2995439
Abstract Full Text PDF–357K Supplementary Material
ACTIVATED PROTEIN C IN SEPSIS: THE PROMISE OF NON-ANTICOAGULANT ACTIVATED PROTEIN C
Hartmut Weiler, Wolfram Ruf
Curr Opin Hematol. Author manuscript; available in PMC 2009 September 11.
Published in final edited form as: Curr Opin Hematol. 2008 September; 15(5): 487–493. doi: 10.1097/MOH.0b013e32830abdf4
PMCID:
PMC2742321
Abstract Full Text PDF–265K
Is There NO Treatment For Severe Sepsis?
AS Bredan, A Cauwels
Libyan J Med. 2008; 3(1): 34–38. Published online 2008 March 1. doi: 10.4176/071018
PMCID:
PMC3074327
Abstract Full Text PDF–54K
Effect of sepsis therapies on health-related quality of life
Sara E Erickson, Greg S Martin
Crit Care. 2008; 12(1): 109. Published online 2008 January 22. doi: 10.1186/cc6215
PMCID:
PMC2374612
Abstract Full Text PDF–40K
Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis
Vania Costa, James M Brophy
BMC Anesthesiol. 2007; 7: 5. Published online 2007 June 25. doi: 10.1186/1471-2253-7-5
PMCID:
PMC1929064
Abstract Full Text PDF–1.0M
Drotrecogin alfa (activated) in patients with severe sepsis and a high risk of death
Jan O Friedrich, Neill KJ Adhikari, Maureen O Meade
Crit Care. 2006; 10(6): 427. Published online 2006 December 20. doi: 10.1186/cc5117
PMCID:
PMC1794484
Full Text PDF–30K
Drotrecogin alfa (activated): current evidence supports treatment for severe sepsis patients with a high risk of death
Mark D Williams, Jonathan M Janes, David R Nelson
Crit Care. 2006; 10(5): 424. Published online 2006 October 30. doi: 10.1186/cc5062
PMCID:
PMC1751048
Full Text PDF–71K
Drotrecogin alfa (activated): down and not out, but not really in either
Jan O Friedrich, Neill KJ Adhikari, Maureen O Meade
Crit Care. 2006; 10(5): 420. Published online 2006 September 22. doi: 10.1186/cc5022
PMCID:
PMC1751078
Full Text PDF–33K
Patience and change: a conflict of interests?
Manoj K Saxena, Peter JD Andrews
Crit Care. 2006; 10(5): 422. Published online 2006 September 19. doi: 10.1186/cc5034
PMCID:
PMC1751066
Full Text PDF–31K
Activated protein C in sepsis: down but not out, yet
Ritesh Agarwal, Alok Nath
Crit Care. 2006; 10(4): 416. Published online 2006 July 26. doi: 10.1186/cc4988
PMCID:
PMC1750980
Full Text PDF–31K
You are here: NCBI > Literature > PubMed Central (PMC)
Write to the Help Desk